Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study

Urologia Internationalis

Volumn 94, Issue 3, 2015, Pages 286-295

  Vahlensieck, Winfried ^a,g   Theurer, Christoph ^b   Pfitzer, Edith ^c   Patz, Brigitte ^d   Banik, Norbert ^e   Engelmann, Udo ^f  

^a Kurpark Klinik   (Germany)

^b Pharmaceutical Chemist   (Germany)

^c Schwäbisch Gmünd   (Germany)

^d Freelance Scientific Consulting   (Germany)

^e Winicker Norimed Medical Research GmbH   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g Kurpark Klinik   (Germany)

Author keywords

Benign prostatic hyperplasia; Cucurbita pepo; International prostate symptom score; Lower urinary tract symptoms; Pumpkin seed; Quality of life

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PLANT EXTRACT; PUMPKIN SEED EXTRACT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; INTENTION TO TREAT ANALYSIS; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NOCTURIA; PLANT SEED; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SQUASH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; LOWER URINARY TRACT SYMPTOMS; MIDDLE AGED; MULTICENTER STUDY; PATIENT SAFETY; PROSTATIC HYPERPLASIA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CUCURBITA; DOUBLE-BLIND METHOD; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PATIENT SAFETY; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SEEDS;

EID: 84928426230     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000362903     Document Type: Article

References (27)

1. German Commission E: Cucurbitae peponis semen. Bundesanzeiger No 223, Nov 30, 1985, correction Bundesanzeiger No 11, Jan 17, 1991.
2. Pater B: Uber die Heilkraft des Kurbissamens. Heil Gewurzpfl 1929; 12: 18-20.
3. Committee on Herbal Medicinal Products (HMPC): Assessment report on Cucurbita pepo L., semen. EMA/HMPC/136022/2010, Nov 20, 2012, fist published March 25, 2013.
4. Nitsch-Fitz R, Egger H, Wutzl H, Maruna H: Einsatz des Kurbiskern-Diatetikums 'Kurbis-Granufink' bei Patienten mit Prostatahypertrophie in Wiener Allgemeinpraxen. Erfahrungsheilkunde 1979; 28: 1009-1013.
5. Nitsch-Fitz R, Egger H, Wutzl H, Maruna H: Ergebnisse einer Praxisstudie uber das Kurbiskern-Diatetikum 'Kurbis-Granufink' bei Patienten mit Miktionsbeschwerden verschiedener Genese. Dr Med 1979; 3: 38-40.
6. Strobl M, Patz B, Bracher F: Kurbissamen bei Storungen der Blasenfunktion. DAZ 2004; 144: 4010-4014.
7. Bracher F, Plossl F: Identification and determination of phytosterols in pharmaceutical preparations. Annu Meet DPhG (Deutsche Pharmazeutische Gesellschaft), Jena, 2009.
8. Abdel-Rahman MK: Effect of pumpkin seed ( Cucurbita pepo L.) diets on benign prostatic hyperplasia (BPH): chemical and morphometric evaluation in rats. World J Chem 2006,1: 33-40.
9. Gossell-Williams M, Davis A, O'Connor N: Inhibition of testosterone-induced hyperplasia of the prostate of Sprague-Dawley rats by pumpkin seed oil. J Med Food 2006; 9: 284-286.
10. Tsai YS, Tong YC, Cheng JT, Lee CH, Yang FS, Lee HY: Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats. Urol Int 2006; 77: 269-274.
11. Zhang X, Ouyang J, Zhang Y, Tayalla B, Zhou X, Zhou S: Effect of the extracts of pumpkin seeds on the urodynamics of rabbits: an experimental study. J Tongji Med Univ 1994; 14: 235-238.
12. Kim SH, Jung KI, Koh JS, Min KO, Cho SY, Kim HW: Lower urinary tract symptoms in benign prostatic hyperplasia patients: orchestrated by chronic prostatic inflammation and prostatic calculi? Urol Int 2013; 90: 144-149.
13. Fahim AT, Abd-El-Fattah AA, Agha AM, Gad MZ: Effect of pumpkin-seed oil on the level of free radical scavengers induced during adjuvant-arthritis in rats. Pharmacol Res 1995; 31: 73-79.
14. Denis L, McConnell JD, Yoshica O, Khoury S, Abrams P, Barry M, et al: Recommendations of the International Scientific Committee: the evaluation and treatment of lower urinary tract syndromes (LUTS) suggestive of benign prostatic obstruction; in Denis L, Griffiths K, Khoury S, et al (eds): Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH). Plymouth, Plymbridge, 1998, pp 669-683.
15. Bach D: Placebokontrollierte Langzeitstudie mit Kurbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Urologe B 2000; 40: 437-443; erratum in Urologe B 2001; 41: 42.
16. Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G: The long-term outcome of medical therapy for BPH. Eur Urol 2007; 51: 1522-1533.
17. MacDonald R, Tacklind JW, Rutks I, Wilt TJ: Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 2012; 109: 1756-1761.
18. Adey GS, O'Leary MP, Barry MJ: Evaluating symptoms and functional status; in Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P (eds): Textbook of Benign Prostatic Hyperplasia. London, Tayler &Francis, 2005, pp 201-209.
19. Dong Y, Hao L, Shi Z, Wang G, Zhang Z, Han C: Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a metaanalysis. Urol Int 2013; 91: 10-18.
20. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'Dow J, Nordling J, de la Rosette JJ: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013; 64: 118-140.
21. Madersbacher S, Ponholzer A, Berger I, Marszalek M: Medical management of BPH: role of plant extracts. EAU EBU Update Ser 2007; 5: 197-205.
22. Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV: The efficacy of drugs for the treatment of LUTS/BPH, a study in 6. European countries. Eur Urol 2007; 51: 207-215.
23. Schneider T, Ruebben H: Stinging nettle root extract (Bazoton uno) in long term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo-controlled multicenter study after 12 months (in German). Urologe A 2004; 43: 302-306.
24. Homma Y, Kawabe K, Tsukamoto T, Tsukamoto R. Yamaguchi O, Okada K, Aso Y, Watanabe H, Okajima E, Kumazawa J, Yamaguchi T, Ohashi Y: Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int J Urol 1996; 3: 267-273.
25. Konstantinidis C, Samainas M, Andreadakis S, Xanthis S, Skriapas K: Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin -a prospective study. Urol Int 2013; 90: 156-160.
26. Səglam HS, Gorkaya CS, Salar R, Memiş A, Adsan O: The effects of age, metabolic syndrome, nocturnal polyuria and sleep disorders on nocturia. Adv Clin Exp Med 2013; 22: 489-494.
27. O'Leary MP: Validity of the 'bother score' in the evaluation and treatment of symptomatic benign prostatic hyperplasia. Rev Urol 2005; 7: 1-10.